Solas Capital Management LLC Purchases Shares of 1,393,328 Alpha Cognition, Inc. (NASDAQ:ACOG)

Solas Capital Management LLC acquired a new position in shares of Alpha Cognition, Inc. (NASDAQ:ACOG) during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 1,393,328 shares of the company’s stock, valued at approximately $8,096,000. Alpha Cognition makes up about 5.4% of Solas Capital Management LLC’s portfolio, making the stock its 9th largest position. Solas Capital Management LLC owned approximately 8.70% of Alpha Cognition as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. National Bank of Canada FI purchased a new stake in Alpha Cognition during the fourth quarter valued at $69,000. MYDA Advisors LLC bought a new position in shares of Alpha Cognition in the 4th quarter valued at about $589,000. Aristides Capital LLC bought a new stake in Alpha Cognition during the fourth quarter worth approximately $1,178,000. ADAR1 Capital Management LLC purchased a new stake in Alpha Cognition during the fourth quarter valued at approximately $1,204,000. Finally, Rosalind Advisors Inc. bought a new stake in shares of Alpha Cognition in the 4th quarter valued at approximately $1,489,000.

Analyst Ratings Changes

Several equities analysts have recently weighed in on ACOG shares. HC Wainwright reissued a “buy” rating and set a $20.00 target price on shares of Alpha Cognition in a research report on Monday, March 31st. Raymond James upgraded shares of Alpha Cognition to a “moderate buy” rating in a research report on Tuesday, March 25th.

Alpha Cognition Stock Performance

ACOG opened at $5.04 on Friday. The company’s 50 day simple moving average is $5.17. Alpha Cognition, Inc. has a one year low of $3.75 and a one year high of $7.00. The company has a market capitalization of $80.74 million, a PE ratio of -1.97 and a beta of 2.50.

Alpha Cognition (NASDAQ:ACOG) last announced its quarterly earnings data on Monday, March 31st. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.03).

Alpha Cognition Company Profile

Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.